Pharmaceuticals: Homing in on new medicines: A clinical database is helping to pinpoint snags with new products earlier
Sunday 18 July 1993
But it also carries great risks. Even a minor scare about the side-effects of a drug can have a dramatic effect on both the share price and the company's reputation.
If a small south London company has its way, however, a number of those risks could be eliminated. The key is a computerised clinical database that currently covers 4.4 million patients treated by about 2,000 general practitioners in the UK.
All new drugs go through rigorous tests before they are made available to the general public. But tough as they are, the tests cannot guarantee that the drug is safe for everybody. It is often only when the drug is out in the market that its makers discover that it causes serious reactions when, for example, it is taken with another drug, or by people of a certain age. Because they do not know the extent of the problem the manufacturers may have no choice but to withdraw it.
Value Added Medical Products of Battersea believes its database holds the answer because it provides much more accurate information about the risks than is currently available. As Ron Mann, a former senior medicines regulator who is now the company's executive medical director, explains, very few active drugs are totally devoid of risk. The key issue is to balance benefit against that risk.
To do this, the number of adverse reactions must be analysed in the light of several factors, including the number of patients who have taken the drug. In most cases, truly accurate information cannot be obtained because the drugs can be prescribed for use against a variety of diseases and for different lengths of time.
Vamp says, however, that its database offers precision because the number of patients who have received the drug is known, while the name of the drug, its dose and instructions are recorded on the computer as the GP issues the prescription. In the same way, the GP will record information about adverse effects as he or she receives it.
As a result, the significance of problems can be quickly assessed. Because the data is being gathered constantly, the value of the information increases as time goes on.
This development has taken Vamp - which was placed top in the Independent on Sunday's first league table of fastest- growing private companies - a long way from its beginnings a decade ago as a supplier of computer systems to medical practices. That, as Mr Williams reflected, was a tricky enough business.
'You are paying to educate the market and it is grindingly hard work,' he explained.
Since then, though, the company has seen off the competition. And that side of the business - a wholly owned subsidiary called Vamp Health - made a pre-tax profit of pounds 1.7m last year on turnover of pounds 13m.
The subsidiary dealing with the database - Vamp Research - was set up only in early 1991, but last year broke even on a turnover of pounds 1.1m. While it is currently using up a great deal of money on research and publishing the results, it has the potential to outstrip the other business through selling its findings to the drug companies.
Some of these are already showing signs of taking safety ever more seriously by removing it from the day-to-day business. One is reported to have set up a separate division.
Consequently, according to Dr Mann, access to high quality and current information is very attractive to the boards of those companies. 'Besides the safety benefit, it allows them for the first time to take a strategic view of the business,' he said.
- 1 Three-year-old ultra-Orthodox Jewish children told 'the non-Jews' are 'evil' in worksheet produced by London school
- 2 Moscow voted the world's unfriendliest city
- 3 The excuses your boss is most likely to believe when you call in sick
- 4 I'm pansexual – here are the five biggest misconceptions about my sexuality
- 5 More than 11,000 Icelanders offer to house Syrian refugees to help European crisis
The excuses your boss is most likely to believe when you call in sick
Bono's group has made more money from Facebook investment than from all his music
Three-year-old ultra-Orthodox Jewish children told 'the non-Jews' are 'evil' in worksheet produced by London school
Wikipedia rocked by 'rogue editors' blackmail scam targeting small businesses and celebrities
More than 11,000 Icelanders offer to house Syrian refugees to help European crisis
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
Jeremy Corbyn calls Osama bin Laden's killing a 'tragedy' - but was it taken out of context?
If these extraordinarily powerful images of a dead Syrian child washed up on a beach don’t change Europe’s attitude to refugees, what will?
If you're not already angry about the refugee crisis, here's a history lesson to remind you why you really should be
Theresa May says migrants should be banned from entering the UK unless they have jobs lined up
Tony Blair attacks Jeremy Corbyn's 'Alice In Wonderland' politics
iJobs Money & Business
£14000 - £16000 per annum: Recruitment Genius: This company was established in...
£20000 - £25000 per annum + OTE 40k: SThree: SThree are a global FTSE 250 busi...
£20000 - £25000 per annum + competitive: SThree: SThree are a global FTSE 250 ...
Voluntary and unpaid, reasonable expenses reimbursable: Reach Volunteering: St...